Infinity Pharmaceuticals, Inc. (INFI) Reaches $2.59 After 6.00% Up Move; Techtarget (TTGT) SI Increased By 22.36%

March 14, 2018 - By Stephen Andrade

Techtarget Inc (NASDAQ:TTGT) had an increase of 22.36% in short interest. TTGT’s SI was 79,900 shares in March as released by FINRA. Its up 22.36% from 65,300 shares previously. With 146,300 avg volume, 1 days are for Techtarget Inc (NASDAQ:TTGT)’s short sellers to cover TTGT’s short positions. The SI to Techtarget Inc’s float is 0.62%. The stock decreased 1.75% or $0.33 during the last trading session, reaching $18.53. About 23,043 shares traded. TechTarget, Inc. (NASDAQ:TTGT) has risen 14.89% since March 14, 2017 and is uptrending. It has underperformed by 1.81% the S&P500.

The stock of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) is a huge mover today! The stock increased 4.86% or $0.12 during the last trading session, reaching $2.59. About 534,649 shares traded. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has declined 60.96% since March 14, 2017 and is downtrending. It has underperformed by 77.66% the S&P500.The move comes after 5 months positive chart setup for the $131.34M company. It was reported on Mar, 14 by We have $2.75 PT which if reached, will make NASDAQ:INFI worth $7.88 million more.

Investors sentiment increased to 0.62 in Q3 2017. Its up 0.15, from 0.47 in 2017Q2. It improved, as 15 investors sold Infinity Pharmaceuticals, Inc. shares while 23 reduced holdings. 6 funds opened positions while 12 raised stakes. 27.30 million shares or 18.05% less from 33.31 million shares in 2017Q2 were reported. Financial Group Inc holds 40,000 shares or 0.01% of its portfolio. Virtu Fincl Ltd Liability, New York-based fund reported 10,339 shares. Guggenheim Cap Limited Company reported 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Vanguard Grp Inc holds 2.35M shares or 0% of its portfolio. Two Sigma Securities holds 20,279 shares. Art Advisors Ltd Liability invested in 0.01% or 181,220 shares. Tortoise Investment Limited Company stated it has 100 shares. Aperio Gp Ltd holds 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 11,161 shares. Meeder Asset invested in 2,638 shares. Wellington Management Group Inc Limited Liability Partnership accumulated 0% or 5.02 million shares. Numeric Limited Co has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Quantitative Invest Mgmt Limited stated it has 46,400 shares. California Public Employees Retirement System invested in 88,100 shares or 0% of the stock. Rock Springs Cap Mngmt Lp holds 270,000 shares or 0.02% of its portfolio. The Maryland-based Price T Rowe Assocs Md has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI).

Analysts await Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to report earnings on March, 15 after the close. They expect $-0.27 earnings per share, up 41.30% or $0.19 from last year’s $-0.46 per share. After $-0.14 actual earnings per share reported by Infinity Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 92.86% negative EPS growth.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. The company has market cap of $131.34 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study. It currently has negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

Among 9 analysts covering Infinity Pharmaceutical (NASDAQ:INFI), 2 have Buy rating, 0 Sell and 7 Hold. Therefore 22% are positive. Infinity Pharmaceutical had 16 analyst reports since August 7, 2015 according to SRatingsIntel. Morgan Stanley downgraded Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) rating on Wednesday, June 15. Morgan Stanley has “Equal-Weight” rating and $1 target. Wedbush upgraded Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) rating on Tuesday, June 14. Wedbush has “Neutral” rating and $1.50 target. downgraded the stock to “Neutral” rating in Tuesday, June 14 report. RBC Capital Markets maintained Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) rating on Friday, August 7. RBC Capital Markets has “Outperform” rating and $15 target. Zacks upgraded it to “Hold” rating and $11 target in Monday, August 10 report. Wedbush downgraded the shares of INFI in report on Tuesday, March 22 to “Underperform” rating. The stock has “Outperform” rating by FBR Capital on Wednesday, March 2. JMP Securities maintained Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) on Wednesday, March 9 with “Market Outperform” rating. The company was upgraded on Monday, September 21 by Morgan Stanley. Jefferies downgraded Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) on Wednesday, June 15 to “Hold” rating.

Since October 3, 2017, it had 1 buying transaction, and 1 insider sale for $1.99 million activity. Perkins Adelene Q sold $13,890 worth of stock or 5,000 shares. On Tuesday, October 3 the insider BVF PARTNERS L P/IL bought $2.01 million.

Investors sentiment decreased to 1.52 in 2017 Q3. Its down 0.27, from 1.79 in 2017Q2. It turned negative, as 1 investors sold TechTarget, Inc. shares while 18 reduced holdings. 15 funds opened positions while 19 raised stakes. 12.31 million shares or 1.36% more from 12.15 million shares in 2017Q2 were reported. Alliancebernstein Ltd Partnership accumulated 21,100 shares. Eam Invsts Ltd Liability Corporation holds 0.09% in TechTarget, Inc. (NASDAQ:TTGT) or 56,028 shares. Trigran reported 2.63M shares. Natl Bank Of Ny Mellon Corp has 77,664 shares for 0% of their portfolio. 956,875 were accumulated by Blackrock. Renaissance Limited Liability Company accumulated 0.01% or 545,170 shares. Moreover, Bank Of America Corporation De has 0% invested in TechTarget, Inc. (NASDAQ:TTGT) for 1,890 shares. Two Sigma Secs has invested 0.01% in TechTarget, Inc. (NASDAQ:TTGT). First Quadrant Lp Ca has invested 0% in TechTarget, Inc. (NASDAQ:TTGT). Credit Suisse Ag holds 0% or 12,874 shares. Goldman Sachs Group Incorporated Inc invested in 10,903 shares or 0% of the stock. Manufacturers Life Insur Com The owns 17,257 shares or 0% of their US portfolio. Morgan Stanley holds 43,827 shares or 0% of its portfolio. Punch And Assoc Investment Incorporated owns 925,420 shares for 0.98% of their portfolio. Ameritas Inv Prns Inc reported 0% in TechTarget, Inc. (NASDAQ:TTGT).

Among 5 analysts covering TechTarget (NASDAQ:TTGT), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. TechTarget had 15 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of TechTarget, Inc. (NASDAQ:TTGT) earned “Hold” rating by Jefferies on Thursday, September 28. Lake Street maintained TechTarget, Inc. (NASDAQ:TTGT) on Thursday, November 10 with “Buy” rating. Jefferies maintained the stock with “Hold” rating in Wednesday, February 7 report. TheStreet upgraded TechTarget, Inc. (NASDAQ:TTGT) on Friday, August 7 to “Hold” rating. The stock of TechTarget, Inc. (NASDAQ:TTGT) has “Buy” rating given on Wednesday, June 21 by Jefferies. On Wednesday, July 20 the stock rating was initiated by Sidoti with “Buy”. The firm has “Buy” rating given on Thursday, August 3 by Jefferies. The firm has “Buy” rating given on Wednesday, February 15 by Lake Street. The company was maintained on Thursday, February 11 by Needham. The firm has “Hold” rating given on Thursday, August 17 by Jefferies.

TechTarget, Inc. provides specialized online content for buyers of corporate information technology services and products; and purchase-intent marketing and sales services for enterprise technology vendors in the United States and internationally. The company has market cap of $509.26 million. It offers customized marketing programs that integrate demand generation and brand marketing, as well as advertising techniques, which enable IT vendors to identify, reach, and influence corporate IT decision makers who are researching specific IT purchases. It has a 77.21 P/E ratio. The companyÂ’s products include IT deal alert, core online, demand solutions, brand solutions, and custom content creation, which are provided through online, as well as operates face-to-face events.

Since September 18, 2017, it had 0 insider purchases, and 16 sales for $5.58 million activity. On Wednesday, February 21 Hawk Don sold $256,800 worth of TechTarget, Inc. (NASDAQ:TTGT) or 15,000 shares. 10,000 shares were sold by Beam Kevin, worth $137,750. Strakosch Greg sold $75,000 worth of stock or 5,000 shares. Nine Ten Partners LP had sold 60,000 shares worth $904,800.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.